Medical Device Regulatory Strategy Development

Why Strategy Comes First

The Most Expensive Regulatory Mistakes Happen at the Beginning

The majority of FDA submission failures, extended review cycles, and clinical program design flaws trace back to strategic decisions made — or not made — in the first phase of product development. A device classified incorrectly that advances through two years of development against the wrong testing standard. A 510(k) built around a predicate that FDA considers too dissimilar. A clinical study designed without alignment with FDA's expected endpoints. A software feature added late in development that triggers cybersecurity review requirements the team was unprepared for.

None of these failures are inevitable — they're the predictable result of entering the regulatory process without a documented strategy. ADB CRO's regulatory strategy engagements exist specifically to surface and resolve these questions before they become expensive problems.

Device Classification: Getting It Right Before Everything Else

Device classification under 21 CFR determines your regulatory pathway, your submission requirements, your quality system obligations, and your labeling requirements. Classification is not always straightforward — many devices span multiple product codes, classification is determined by intended use (not technology), and a device with a broader intended use statement may fall into a higher risk class than the same device with a narrower one.

We conduct systematic classification analyses using 21 CFR Parts 862–892, FDA's product code database, and — for novel devices — the 513(g) Request for Designation process to obtain FDA's official classification determination. Where classification is genuinely ambiguous, we use the 513(g) process strategically: the written determination creates a documented record that protects against classification disputes later in the review process.

Pathway Selection: Building in Contingencies

Regulatory pathway selection — 510(k), De Novo, PMA, or exempt — is the single most consequential strategic decision in device development. Each pathway has different evidentiary requirements, review timelines, post-market obligations, and cost implications. The right pathway is not always the fastest one. A 510(k) built on a weak predicate that results in an NSE determination, followed by a De Novo that could have been filed directly, costs more time and money than a well-planned De Novo from the outset.

We build regulatory strategy documents that identify the primary pathway, evaluate the strength of the primary pathway's evidence base, and define contingency pathways with decision criteria. If the primary 510(k) predicate doesn't hold up under FDA scrutiny, what is the backup? If the PMA clinical trial generates unexpected safety signals, what is the protocol deviation plan? These contingencies are not pessimism — they are the difference between a regulatory program that adapts and one that stalls.

Connecting Regulatory Strategy to Development Programs

Regulatory strategy has limited value if it exists in isolation from product development. Design controls (21 CFR Part 820.30), risk management (ISO 14971), and regulatory submission strategy need to be connected from day one. Testing conducted without consideration of the submission it needs to support may be well-executed science that doesn't meet FDA's evidentiary standard. Design changes made late in development without regulatory impact assessment can trigger design history file amendments, reclassification risk, or new submission requirements.

We integrate regulatory strategy into development stage gates — defining what regulatory documentation is required at each milestone, what testing must be complete before certain development decisions are locked, and what FDA expectations apply at each phase of the program.

What We Deliver

• Device classification analysis and 513(g) Request for Designation (if needed)
• Regulatory pathway analysis: 510(k), De Novo, PMA, and exemption assessment
• Written Regulatory Strategy Document with primary and contingency pathways
• Predicate analysis: candidate predicates evaluated against SE standard
• Testing strategy framework: required tests, applicable standards, acceptable methods
• Pre-Submission meeting strategy and agenda development
• Design controls integration plan: regulatory checkpoints in the development stage gate
• Global regulatory alignment (EU MDR, Canada MDSAP, Japan PMDA) if applicable
• Post-market surveillance and lifecycle regulatory planning
• Regulatory strategy review and update as development evolves

Develop Your Regulatory Strategy